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Abstract
Polymorphisms in and around the Cholesteryl Ester Transfer Protein (CETP) gene have been associated with HDL levels, risk
for coronary artery disease (CAD), and response to therapy. The mechanism of action of these polymorphisms has yet to be
defined. We used mRNA allelic expression and splice isoform measurements in human liver tissues to identify the genetic
variants affecting CETP levels. Allelic CETP mRNA expression ratios in 56 human livers were strongly associated with several
variants 2.5–7 kb upstream of the transcription start site (e.g., rs247616 p= 6.461025, allele frequency 33%). In addition, a
common alternatively spliced CETP isoform lacking exon 9 (D9), has been shown to prevent CETP secretion in a dominant-
negative manner. The D 9 expression ranged from 10 to 48% of total CETP mRNA in 94 livers. Increased formation of this
isoform was exclusively associated with an exon 9 polymorphism rs5883-C.T (p = 6.8610210) and intron 8 polymorphism
rs9930761-T.C (5.661028) (in high linkage disequilibrium with allele frequencies 6–7%). rs9930761 changes a key splicing
branch point nucleotide in intron 8, while rs5883 alters an exonic splicing enhancer sequence in exon 9. The effect of
these polymorphisms was evaluated in two clinical studies. In the Whitehall II study of 4745 subjects, both rs247616 and
rs5883T/rs9930761C were independently associated with increased HDL-C levels in males with similar effect size (rs247616
p= 9.6610228 and rs5883 p= 8.6610210, adjusted for rs247616). In an independent multiethnic US cohort of hypertensive
subjects with CAD (INVEST-GENE), rs5883T/rs9930761C alone were significantly associated with increased incidence of MI,
stroke, and all-cause mortality in males (rs5883: OR 2.36 (CI 1.29–4.30), p = 0.005, n = 866). These variants did not reach
significance in females in either study. Similar to earlier results linking low CETP activity with poor outcomes in males, our
results suggest genetic, sex-dependent CETP splicing effects on cardiovascular risk by a mechanism independent of
circulating HDL-C levels.
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Introduction
CETP shuttles cholesterol esters from high-density lipoprotein
particles (HDL) to low density lipoproteins (LDL). High CETP
activity lowers the HDL/total cholesterol ratio, potentially
increasing risk for coronary artery disease (CAD). Therefore,
inhibition of CETP offers a new approach to CAD therapy [1,2].
However, the CETP inhibitor torcetrapib was found to increase
cardiovascular events, even though HDL increased and LDL
decreased substantially [3]. As LDL supports reverse cholesterol
transport to the liver, patients with rare genetic defects in CETP
present with numerous lipid abnormalities [4]. Recent results
further question the validity of the CETP-HDL-CAD relationship
under all conditions, showing that low CETP levels can associate
with increased CAD risk [5], possibly because of functions other
than cholesterol transport.
CETP is highly polymorphic. Clinical studies have demonstrated
a robust association of the Taq1B allele in intron 1 (rs708272C.T;
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TaqIBB, minor allele frequency (MAF) 0.44) with lowCETP activity,
decreased total cholesterol, and increased HDL cholesterol (HDL-
C) [6–12]. In addition, TaqIBB was correlated with poor response to
pravastatin in male but not female CAD patients [13–15]. While
this finding has not been replicated in other studies [16–18], CETP
polymorphisms appear to affect cardiovascular risk and therapy in a
sex-dependent manner, reflecting different lipid metabolism in
males and females [13–15]. However, TaqIB appears to serve
merely as a surrogate marker for promoter/enhancer polymor-
phisms [19–25], and the responsible regulatory polymorphisms
remain uncertain. Non-synonymous polymorphisms, such as
rs5882A.G (I405V), have also been suggested to affect CETP
function, but definitive data are lacking.
Alternative splicing also affects CETP activity. An in-frame
deletion of exon 9 (D9) generates a shorter D9 protein, which
dimerizes with the full-length form preventing its efflux from the
liver [19,26], possibly acting in a dominant negative manner.
While production of the D9 splice variant is influenced by diet
[27,28], genetic factors have yet to be determined. To search for
regulatory variants affecting CETP mRNA expression and test for
the presence of genetic effects on splicing, we measured allelic
mRNA expression and splicing in human livers, identifying
candidate promoter/enhancer SNPs located 2.5–7 kb upstream,
and discovering two SNPs in near complete linkage disequilibrium
(LD) tightly associated with D9 CETP splicing. We then asked
whether these polymorphisms affect HDL-C and risk for
myocardial infarction.
Results
Total CETP mRNA levels in human livers and CETP
genotype
PCR cycle thresholds (CTs; mean 27.961.1 SD) varied
considerably for CETP mRNA between tissues. To scan the
CETP locus for polymorphisms associated with mRNA expression,
we genotyped multiple SNPs spanning ,37 kb (Figure S1, Table
S1). None of these SNPs yielded a robust association with overall
mRNA levels, consistent with earlier results [23].
Allelic CETP mRNA ratios in liver
Using the SNaPshot TM primer extension assay, allelic mRNA
ratios were measurable in 56 livers with rs5882 as the marker SNP.
Significant allelic expression imbalance (AEI) was detectable in 29
of 56 livers tested (AEI ratios log2.0.4, or .30% below or above
the mean gDNA ratio). The allelic mRNA ratios were distributed
above and below the mean DNA ratio, indicating the presence of
one or more cis-acting regulatory polymorphisms present in low
LD with the marker SNP rs5882. Scanning the CETP locus with
13 SNPs genotyped in livers (Table S2), we determined SNP
associations with presence of absence of AEI, or AEI ratios as
continuous variable (absolute log ratios only). An LD structure
map showing r2 and D9 values between all 13 SNPs is presented in
Figure S5. Shown in Figure 1A, three SNPs located 2.6–7 kb
upstream scored significantly (rs173539, rs247616, and
rs3764261), with rs247616 having the strongest association
(p = 6.461025), indicating that transcription is under genetic
control by these variants or others in high LD across the large 59-
haplotype block. Previously proposed promoter SNPs did not
score significantly (Figure 1A). The allelic mRNA ratios differed
strongly between genotypes of rs247616 (Figure 1B)
Association of CETP exon 9 rs5883IC.T and intron 8 SNP
rs9930761T.C with the D9 CETP mRNA splice variant in
liver
Measured with fluorescently labeled PCR primers, the D9 splice
variant accounted for 10% to 48% of total CETP mRNA in 94
livers analyzed. An initial CETP SNP scan first revealed an
association of I405V (rs5882) and G84A in the 39UTR (rs1801706)
with increased D9 splice variant, suggesting the presence of a
Figure 1. Association of CETP SNPs with Allelic Expression Ratios. Panel A. Association of each SNP with RNA absolute allelic ratios, as
measured using rs5882 as an indicator. * Since rs5882 is used as the indicator in the assay, the p value is not applicable. The allelic mRNA ratios were
normalized to the overall mean allelic gDNA ratios (there was no indication of a gene dosage effect requiring normalization to the gDNA for each
individual). The data are mean 6 S.D. (n = 3–6). Panel B. Log2 AEI absolute values in rs247616 genotypes. There would not be a detectable difference
in allelic expression of homozygous samples if the SNP is functional.
doi:10.1371/journal.pone.0031930.g001
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splicing polymorphism. Sequencing a 3128 bp CETP genomic
DNA region containing exon 8 through exon 10 in 6 liver tissues
with low and high D9 splice variant expression yielded only two
SNPs, in intron 8 (rs99300761T.C) and exon 9 (rs5883), present
in all three tissues with high, and absent in those with low D9
expression. In 94 livers, rs5883 and rs9930761 (in complete LD
(D9=1); MAF 5.9% and 6.9%%, respectively) were the only SNPs
strongly associated with the D9 splice variant (p = 3.5E220 and
p= 1.7E217, respectively) (Figure 2A). Levels of the D9 splice
variant were markedly higher in rs5883T carriers (mean 39%,
range 25–48% of total CETP mRNA) and in rs9930761C carriers
(mean 36%, range 18–48%; compared to non-carriers (mean
20%, range 10–31%) (Figure 2B). There were no samples
homozygous for the minor allele. Two subjects were heterozygous
for rs9930761 but not rs5883. Both livers had a relatively low
content of the D9 splice variant (18%), accounting for the lower p
value of rs9930761 than of rs5883.
Both rs9930761 and the synonymous SNP rs5883 have potential
impact on the splicing process. The exonic rs5883 minor alle-
le disrupts an exonic splicing enhancer site for SC35
(GTCTTCCA.GTCTTTCA) (ESE finder site (http://rulai.cshl.
edu/cgi-bin/tools/ESE3/esefinder.cgi?process = home) (Figure 3).
In addition, the rs5883 SNP alters predicted mRNA folding
throughout exon 9, as calculated withMfold (Figure S2). The minor
C allele of rs9930761 disrupts a predicted splicing branch point
(Figure 3).
CETP haplotypes
While pair-wise LD analysis confirms the presence of two main
59 and 39 haplotypes blocks, using Helix Tree genetic analysis
software package (Golden Helix, Inc., Bozeman, MT) [29] a 6-
SNP haplotype analysis (rs173539, rs708272 (Taq1B), rs9930761
(or rs5883), rs5882 (I405V), and rs1801706 (G84A)) reveals the
presence of only a few long-range haplotypes (Table S3). The
minor C/T alleles of rs9930761/rs5883 are nearly exclusively
embedded in a haplotype consisting of the wild-type alleles of
Taq1B (intron 1) and rs173539 (upstream enhancer region), and
the minor alleles of I405V (G) and G84A (A) accounting for weak
associations of I405V and G84A with splicing (Figure 2A). Since
the wild-type alleles of Taq1B and rs173539 (in high LD with
rs247616) are associated with higher CETP levels and reduced
HDL-C, the effects of rs5883/rs9930761 on HDL-C must be
considered conditional on the upstream promoter SNPs.
Association of rs5883/rs9930761 with HDL-C levels in
Whitehall II
Of 95 CETP SNPs genotyped in 4,745 subjects, many SNPs
were strongly associated with HDL-C, largely owing to high LD
among them (e.g., rs247616 p= 7.18E229), while, rs5883 and
rs9930761 had lower significance (p= 6.09610E26, and
p= 0.0012, respectively) (Table S4 A). The better score for
rs5883 (Minor Allele Frequency 5.5%) versus rs9930761 (MAF
6.7%) in this cohort supports a critical role for rs5883 while a
contribution from rs9930761 cannot be excluded. The lower
overall significance for rs5883 and rs9930761 is partially
accounted for by low allele frequency compared to enhancer
region SNP rs247616 (33.6%). We then estimated associations of
rs5883/rs9930761 with HDL-C by adjusting for rs247616,
grouped by sex (females have higher HDL-C levels than males)
(Table 1). The p values for both rs5883 and rs9930761 in males,
when made contingent upon rs247616, decreased to p= 8.6E-10
and 3.8E-07, respectively (Table 1). Each minor allele of either
rs5883/rs9930761 or rs247616 was independently associated with
a substantial increase in HDL-C (,0.1 mmol/L/minor allele)
(Table S4 B), showing significant interactions between them
(p= 0.00033; Table S4 C).
Effect of CETP rs5883/rs9930761 on risk of MI and other
primary events in INVEST-GENES
This nested case–control study specifically tested the main
hypothesis whether rs5883/rs9930761 affects risk of primary
outcome events (cases: MI, stroke or all-cause mortality) in
Figure 2. Association of CETP SNPs with the Dsplice variant. Panel A: Association p values assessing relationship between CETP SNPs and D9
splice variant formation in human livers (n = 94). Only rs9930761 and rs5883 in exon 8–10 region can account for increased formation of the D9 splice
variant. rs289714 (intron 9), rs5882 (I405V), and rs1801706 (G84A) show varying degrees of LD with rs9930761, accounting for the observed
association p values. Details for the SNPs in this study are provided in Table S3. Panel B: Percent D9 splice variant of total CETP mRNA as a function of
rs5883T.C and rs9930761C.T. Homozygous minor allele carriers for rs5883/rs9930761 were not observed. All livers were heterozygous for both
rs9930761 and rs5883, except for two livers heterozygous only for rs9930761, indicating that rs5883 is necessary for enhanced splicing. Using ANOVA
with Dunnett’s post-test, p values for both homozygous vs. rs9930761 and vs. rs5883 are P,0.01.
doi:10.1371/journal.pone.0031930.g002
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INVEST-GENES patients, in comparison to other regulatory
variants that also increase HDL-C. With stratification by
genotype, sex and race, significant associations were observed
only in the Caucasian group (866 subjects, Table S5 A; other
groups were too small). White male subjects, but not females,
carrying the minor rs5883T and rs9930761C alleles (MAF 6.0%
and 7.3%, respectively; D9=1,r2 = 0.88), had significantly in-
creased risk of progression to first event (males p = 0.0018–0.0019,
respectively, females p = 0.73–0.90) (Table 2, Table S5 A). The
odds ratios for rs5883T and rs9930761C male carriers were 2.36
and 2.24, respectively (95% CI 1.29–4.30 and 1.28–3.91;
p = 0.0051 and 0.008). Risk for white males without statin therapy
was also substantial (OR 2.0; p = 0.034), but risk in the smaller
statin-treated male group did not reach significance (rs9930761
carriers (OR 2.8; p = 0.089). Therefore, rs5883/rs9930761
appeared to be a general risk factor for male subjects, but larger
cohorts are needed to assess the interaction with statin therapy.
The associations of additional CETP SNPs with outcomes are
shown in Table S5 A, separated by males and females. Sex-
dependent unadjusted p values of p,0.05 were observed for
several SNPs, e.g., enhancer region rs12708967 (males p = 0.012
and females p = 0.77). The same SNPs also showed highly
significant associations HDL levels (rs12708967 p= 1.8E219)
(Table S5 B). However, some enhancer/promoter region SNPs
scored only nominally significant in males and others in females
(e.g., rs6499861), with p values that do not survive multiple
hypotheses adjustments (necessary here because we have yet to
identify the exact SNPs associated with transcription). Moreover,
enhancer region rs247616 (strongly associated with AEI and
HDL-C) failed to show significant association in INVEST-GENES
(p = 0.592 in males and p= 0.067 in females). These results suggest
that the promoter/enhancer SNPs did not show a detectable effect
on outcomes in INVEST-GENES, in contrast to strong effects on
HDL-C.
Figure 3. Schematics of the genomic CETP region spanning exons 8–10. The exonic enhancer site (ESE) in exon 9 is disrupted by rs5883.
Splice site sequences and the predicted splice branch point with rs9930761 are also depicted.
doi:10.1371/journal.pone.0031930.g003
Table 1. Association analysis of HDL-C levels with rs9930761T.C and rs5883C.T, with and without adjusting for upstream SNP
rs247616C.T, in the Whitehall II Study.
Male subjects
SNP position Subject number b P conditional on
rs247616 26152 C.T 3332 0.072 (0.0065) 9.6E-28 -
rs9930761 Intron 8 T.C 3493 0.033 (0.012) 0.0078 -
rs9930761 Intron 8 T.C 3329 0.065 (0.013) 3.8E-07 rs247616
rs5883 Exon 9 C.T 3329 0.052
(0.013)
8.6E-05
rs5883 Exon 9 C.T 3329 0.084
(0.014)
8.6E-10 rs247616
Female subjects
rs247616 26152 C.T 1181 0.067 (0.011) 9.2E-10 -
rs9930761 Intron 8 T.C 1247 0.024 (0.019) 0.20 -
rs9930761 Intron 8 T.C 1179 0.045 (0.019) 0.016 rs247616
rs5883 Exon 9 C.T 1181 0.047
(0.021)
0.024
rs5883 Exon 9 C.T 1181 0.069
(0.021)
0.001 rs247616
Minor allele frequency (MAF) was 6.7% for rs9930761, 5.5% for rs5883, and 33.6% for rs247616. Linkage disequilibrium (LD) for rs247616–rs9930761 is R2 = 0.035 and
D9=0.962 (haplotype frequencies are (versus expected under linkage equilibrium) TC 0.001 (0.023), CC 0.067 (0.044), TT 0.337 (0.315), and CT 0.595 (0.618). Note that the
minor alleles rarely occur together (TC 0.001), indicating a strong negative LD between rs9930761/rs5883 and rs247616, requiring HDL-C versus rs9930761/rs5883
analysis conditional on rs247616. For all SNPs see Supporting Information Table S4.
doi:10.1371/journal.pone.0031930.t001
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Discussion
This study identifies two CETP SNPs strongly associated with
splicing to a D9 CETP protein thought to act in a dominant-
negative fashion. Both rs5883 and rs9930761 show significant
associations with HDL and clinical outcomes in cardiovascular risk
patients. Previously described CETP polymorphisms in a 59
haplotype block affecting transcription also score highly with
respect to HDL levels but failed to carry significant associations
with clinical outcomes. Allelic CETP mRNA ratio analysis in
human livers identified a region 2.5–7 kb 59 upstream of the
transcription start site, with at least three abundant SNPs, including
rs247616, that are strong candidates as regulatory factors.
Identification of promoter/enhancer SNPs affecting CETP
mRNA expression
Using allelic CETP mRNA ratios measured in human livers, we
have identified at least three upstream promoter/enhancer SNPs
(rs173539, rs247616, and rs3764261) strongly associated with
expression. Several of the SNPs tested here and previously
proposed to have regulatory impact on transcription did not score
significantly. This approach based on a highly reproducible
proximate phenotype (allelic mRNA ratios) and SNP-scanning a
gene locus has proven powerful for detecting regulatory variants
[30]. Further extensive molecular studies are needed to determine
which regulatory variant(s) modulate CETP expression, with
multiple candidates contained in the 59 haplotype block.
rs5883/rs9930761 disrupts CETP mRNA splicing to yield
the D9 splice variant
Formation of the D9 splice variant in human livers was
associated with two SNPs in high LD (D9=1) with each other,
intron 8 (rs9930761T.C; 5–7% allele frequency in Caucasians
and,11% in subjects of African descent) and exon 9 (rs5883, with
slightly lower minor allele frequency). rs5883 appears to be
necessary for enhanced deletion of exon 9, judged by the relatively
low D9 splice variant content in two livers heterozygous only for
rs9930761 but not rs5883. However, all livers with high D9 splice
variant content were heterozygous for both rs9930761 and rs5883,
suggesting that both may be required to achieve effective skipping
of exon 9. It is remarkable that the LD between the two SNPs is
nearly complete even in African populations, residing predomi-
nantly in a single haplotype stretching over at least 20 kb,
suggesting this represents an evolutionarily conserved haplotype.
The rs5883T allele disrupts an ESE enhancer consensus site and
is predicted to alter RNA folding of the entire exon 9 (Figure S2).
The rs9930761C allele, located 40 bp’s upstream of exon 9,
modulates a splicing branch point consensus sequence CT.CRAY
required in mammalian splicing (Figure 3) [31]. With the intron 8
wild-type sequence CTGAG already predicted to be a weak branch
point, low level of exon 9 skipping does occur in livers. Moreover,
transfection of a minigene construct resulted in predominant exon
9 skipping (80–90%; data not shown), supporting the view that the
splice branch point is already compromised in the wild-type
sequence. As none of the livers were homozygous for the minor
splicing allele, the maximum measured level of 48% D9 formation
in heterozygotes represents a high degree of exon 9 skipping of the
variant rs5883/rs9930761 alleles. No other CETP SNPs account
for the observed genetic effect on splicing.
The biological effect of exon 9 deletion could be amplified by
dominant-negative interactions through heterodimer formation of
the D9 splice variant with full-length CETP, preventing cellular
exit of mature CETP protein [19,26–28]. Splicing in tissues other
than the liver remains to be studied.
Association of promoter/enhancer SNPs and rs5883/
rs9930761 with HDL-C levels
A previous analysis of the Whitehall II study [25] showed that
SNPs in CETP were predominantly associated with HDL-C and
apoAI but less so or not at all with LDL-C, apoB, or TG. Strong
HDL-C associations were observed with a series of promoter/
enhancer SNPs present at high frequency (.30%) (e.g., for
rs247616 p= 6.14E229), consistent with previous results [19–25],
whereas the association was relatively weaker for rs9930761 and
rs5883 (Table S4 A), seemingly indicating less clinical relevance.
However, haplotype estimates revealed that rs5883T/rs9930761C
predominantly share a haplotype consisting of the main wild-type
alleles (associated with high HDL- levels) of all high scoring SNPs
in the promoter/enhancer region (Table S3). Adjusting for
enhancer SNP rs247616, the HDL-C association strengthened
for both rs9930761 and rs5883 (p = 8.6E210 in males) (Table 1).
rs5883 consistently scored with greater significance than rs993
0761, the latter with ,1% greater allele frequency, supporting the
notion that rs5883 is necessary for exon 9 skipping, while
rs9930761 is insufficient but may also be required. A strong
interaction was observed for effects on HDL-C between rs247616
and the splicing SNPs (interaction model p = 0.00033), consistent
Table 2. Associations between CETP rs9930761 and rs5883 minor variant carriers versus homozygous wild-type carriers, sex, race,
and primary event (myocardial infarction, stroke or death) in INVEST.
group rs9930761 Genotype # Odds ratio 95% CI p value SNP*statin interaction p value
White female TT 347 (ref)
TC/CC 55 1.03 0.50–2.14 0.93 0.36
White male TT 395 (ref)
TC/CC 69 2.16 1.22–3.82 0.008 0.9
group rs5883 Genotype # Odds ratio 95% CI p value SNP*statin interaction p value
White female CC 360 (ref)
CT/TT 43 1.02 0.45–2.35 0.96 0.23
White male CC 405 (ref)
CT/TT 59 2.36 1.29–4.30 0.0051 0.64
Odds ratios represent occurrence of primary event for rs9930761/rs5883 carriers versus homozygous wild-type carriers (for all SNPs see Supporting Information Table S5
A).
doi:10.1371/journal.pone.0031930.t002
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with their location on different haplotypes and mechanistically
distinct effects. Considering the combined effects of rs247616 and
rs5883 reveals that each minor allele appears to incrementally
increase the HDL levels (Table S4 B). In particular, carriers
heterozygous for both SNPs (n= 142) have substantially higher
HDL (1.67 +/2 0.48 mmole/L compared to carriers of a minor
allele in only one SNP (1.43 and 1.45 mmole/L) and carriers of
only the main alleles (1.35 +/2 0.37 mmole/L) (Table S4 B).
Homozygous carriers of the minor alleles of rs247616 (n= 516)
were at 1.55 +/2 0.43 mmole/L. The groups with other allele
combinations had much fewer subjects because of the negative LD
between the two SNPs, and therefore could not be evaluated.
Reported rs9930761 and rs5883 allele frequencies differ
between ethnic groups, while maintaining high LD and r2,
ranging from 0% in Asians, and 7.5% in Caucasians to 12.5% in
Yorubans (Table S6 for rs9930761). In a Yoruban population,
rs9930761 allele frequency was reported to be 4% in subjects with
low HDL levels, and 16% in those with high HDL, suggesting a
large effect on HDL in this population (Table S6). Taken all results
together, we conclude that rs5883 and rs9930761 have strong
effects on HDL-C, independent of the upstream promoter/
enhancer SNPs for which Taq1B typically has served as a surrogate
if not suboptimal marker.
CETP genotype effect on progression to event in the
INVEST-GENE study
While the genotyping array contains 95 CETP SNPs, the
present study on patients with pre-existing coronary artery disease
and high blood pressure focuses on a single hypothesis, namely,
whether the newly discovered splicing SNPs have clinical
relevance. Even though present at relatively low allele frequency,
rs5883T/rs9930761C were significantly associated with risk for an
event (either MI, stroke, or death), in males (rs5883 in Caucasians,
OR 2.36; 95% CI 1.29–4.3, p = 0.0051) (Table 2 and Table S5 A;
other groups were too small to assess ethnic differences). As no
significant association was observed in females, we propose that
this effect is sex-dependent, as previously suggested for the
influence of CETP variants on outcomes [13–15]. In contrast to
the interactions between the promoter/enhancer SNPs observed
with HDL-C, there was no discernible interaction with respect to
outcomes, consistent with the notion that the promoter enhancer
variants have no effect, or the effect is too small to be observed in
this cohort. Given the relatively low allele frequency of the splicing
variants and the high odds ratios, the influence of the splicing
SNPs on outcomes appears to be substantial.
Elevated HDL-C levels associated with rs5883T/rs9930761C
would normally be considered protective. However, this subgroup
of male patients may suffer MI’s with primary causes other than
aberrant lipid metabolisms. Also, CETP may have distinct
biological effects not reflected in overall HDL and LDL levels,
including anti-inflammatory properties [32] that could have been
compromised by exon 9 deletion.
In conclusion, the clinical outcome studies suggest that rs5883/
rs9930761 are predictive of increased primary events (MI, stroke
and death) in male at-risk patients. The results reported here
support CETP variants as a potential disease markers and
predictor of statin therapy outcome, and in evaluating CETP
inhibitor drugs, such as torcetrapib [3], in the treatment of
coronary artery disease.
Limitations of the study
While the liver results strongly implicate rs5883/rs9930761 as a
causative factor in CETP mRNA splicing, further molecular
studies are needed to resolve the mechanism and regulation of
splicing, and to identify the regulatory variant(s) affecting
transcription. Also, our results leave open whether rs5883/
rs9930761 are risk factors independent of statin use or affect MI
risk under statin therapy in males, or both. Lastly, the important
conclusion that male CAD patients with specific CETP genotypes
may be at elevated risk of MI incidence or other outcomes has
been drawn from a patient registry not specifically designed for
this study, requiring independent replication.
Materials and Methods
Study samples
Human liver tissues. Frozen human liver samples (125
normal liver biopsy and autopsy samples) were obtained from The
Cooperative Human Tissue Network, Midwestern and Western
Divisions, which is funded by the National Cancer Institute. Other
investigators may have received specimens from the same subjects.
CHTN specimens are derived from material that is removed as
part of routine medical care or autopsy specimens collected in
accordance with operative state and local law. Every CHTN
institution has obtained human subjects assurance from the Office
of Human Research Protections, DHHS. The Assurance
document provides agreement that the institution will comply
with federal human subjects regulations. Each Division of the
CHTN is approved by its local IRB to collect and distribute
biospecimens. Collection to processing intervals were ,24 hours.
Whitehall II study
Between 1985 and 1988, all civil servants aged between 35 and
55 years in 20 departments in London were invited to a medical
examination at their workplace [33]. Follow-up visits took place
every two years. In the present analysis, CETP association with
HDL was limited to white subjects (n = 4745) [25]. The WHII
study was approved by the UCL Research Ethics Committee, and
participants gave written informed consent to each aspect of the
study. Ethics approval was obtained at all hospitals or institutions
where participants were recruited.
INVEST-GENES
The INternational VErapamil SR Trandolapil Study (INVEST)
[34] evaluated adverse cardiovascular outcomes following ran-
domized treatment with either an atenolol- or a verapamil-based
treatment strategy in 22,576 patients aged 50 years or older, with
documented CAD and essential hypertension as defined by JNC
VI [34]. Primary outcomes were first occurrence of all-cause
mortality, nonfatal myocardial infarction (MI), or nonfatal stroke.
From 5,979 INVEST patients from 213 sites in the USA and
Puerto Rico providing DNA samples, a nested case–control study
was designed with 292 INVEST-GENES patients experiencing
primary outcome events during follow-up (cases) and 1168
individuals who did not, frequency-matched to cases for age (by
decades), sex, and race/ethnicity in a ratio of approximately 4:1
(controls/cases), an approach shown to yield equivalent results to
analyses of the entire cohort [35]. All patients provided written
informed consent for participation in the main INVEST and in
the genetic substudy and both studies were approved by the
University of Florida Institutional Review Board.
RNA and DNA preparation from liver tissues
RNA was extracted from 125 biopsy or autopsy liver tissues.
Frozen tissue samples were pulverized under liquid nitrogen. RNA
was extracted using TRIZOL TM, followed by DNase treatment
and Qiagen RNeasy column purification. cDNA was generated
from 1 mg purified mRNA using the Superscript II kit (Invitrogen,
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Carlsbad, CA) with oligo-dT and CETP gene-specific primers.
Liver DNA was prepared by digestion of pulverized frozen liver
tissue in Tris EDTA buffer containing proteinase K and SDS,
followed by NaCl salting-out of proteins and ethanol precipitation
[36].
Quantitative RT-PCR (qRT-PCR) analysis of CETP mRNA
Real-time PCR was performed on an ABI 7000 instrument
using ABI SYBR Green master mix (primer sequences in Table
S1). Beta-actin and CETP-specific primers amplified with .99%
efficiency.
Allelic CETP mRNA expression in human liver tissues
As an accurate measure of cis-acting regulatory factors, allelic
mRNA ratios were measured after conversion to cDNAs and PCR
amplification, using a primer extension method (SNaPshot, Life
Technologies, Foster City, CA) [30]. Allelic mRNA ratios were
normalized to gDNA ratios (standardized to 1, SD 60.03).
Standard curves with cloned cDNAs representing the two alleles
gave straight lines with R2= 0.99 (Figure S3.). Standard deviations
for each individual allelic mRNA ratio ranged from 3–8%. We
also employed allele-selective qRT-PCR, which yielded similar
allelic mRNA ratios compared to SNaPshot R= 0.89, (Figure S4),
supporting accuracy of the results.
Quantitative analysis of CETP D9 splice variant using RT-
PCR with fluorescently labeled primers and splice variant-
specific qRT-PCR
Splice variants were simultaneously PCR amplified using one
set of splice-specific (D9 and long splice variant) forward primers
and a common 6-FAM-fluorescently labeled reverse primer in a
Sigma Ready Mix solution (Sigma Aldrich, St. Louis, MO)
primers: Table S1). Liver cDNA was PCR-amplified for 25
cycles yielding amplicons of 409 bp (D9) and 450 bp (long), and
the fluorescent peaks were analyzed on an ABI 3730 sequencer,
using Gene Mapper version 3.1 (Life Technologies, Foster City,
CA). Independent analysis using quantitative RT-PCR with
SYBR-Green gave similar results (R2 = 0.86; Figure S4.).
Cloned fragments of full length CETP and the D9 splice variant
were used to establish linearity of the assay R2.0.99 (Figure
S3.).
Genotyping
Multiple methods, including TaqMan, fluorescent restriction
mapping and GC clamped allele-specific PCR [37],were used to
genotype 13 CETP SNPs in liver (see Table S2). These are
standard methods used for low throughput genotyping. All clinical
study cohorts were genotyped using the Illumina (Illumina Inc.
San Diego, CA, USA) IBC Candidate Gene array, version 2
(WHII) [25] or version 3 (INVEST-GENES), representing
between 49,094 (v2) to 53,831 (v3) SNPs covering ,2,100
cardiovascular candidate loci, with 95 CETP SNPs [25]. The
content for the custom array was chosen based on published
scientific literature, cardiovascular disease pathway analysis, and
recent whole-genome analysis data sets. The researchers used
Illumina’s iSelect Custom Genotyping BeadChip to assess the
genetic diversity within pathways of approximately 2,100 genes
believed to underpin primary and secondary vascular disease
processes. See Table S4 for additional details. SNPs with a less
than 95% call rate were excluded. Individuals with a call rate less
than 95%, related samples, and population outliers were excluded
using PLINK [38] and EIGENSTRAT. Hardy– Weinberg
Equilibrium was evaluated using chi-squared test.
Sequencing CETP exon 8 to exon 10 splice region
We sequenced a 3.1 kilobase fragment of the CETP exon 8–10
region in 6 livers with high or low D9 splice formation. Three
segments of approximately 1200 bases each were PCR amplified
and Sanger sequenced in both directions on an ABI 3730. The
CETP sequences obtained corresponded to published DNA
sequence. All variants were identified by previously assigned rs
numbers.
Statistical Methods
Statistical analysis of associations between CETP polymor-
phisms and allelic mRNA ratios or percent splice D9 splice variant
was performed using the Helix Tree genetic analysis software
package (Golden Helix, Inc., Bozeman, MT) [29]. Splicing was
analyzed using a both Genotype and Basic Allele Tests. Allelic
mRNA ratios were analyzed with genotype tests. F-Test p values
are reported. Pair-wise linkage disequilibrium (LD) was deter-
mined for each combination of liver SNPs, also using Helix Tree
software See Figure S5 for L.D. plot. Haplotypes were predicted
with the Helix Tree estimation-maximization algorithm.
Association between CETP SNPs and HDL-C in the
Whitehall II study
Two (rs173539 and rs3816117) out of 13 SNPs investigated in
vitro were not present on the Illumina IBC Candidate Gene array,
version 2. These two, and additional CETP SNPs, were imputed
from the HapMap3 and 1000 Genomes Project CEU datasets
using the IMPUTEv2 software (http://mathgen.stats.ox.ac.uk/
impute/impute_v2.html). CETP SNP association analysis with log-
transformed HDL was carried out using PLINK (http://pngu.
mgh.harvard.edu/purcell/plink/) [38], assuming an additive
model. The additive model was used in order to maximize the
prediction quality of the dependent variable from various
distributions. For the additive effects of SNPs, the direction of
the regression coefficient represents the effect of each extra minor
allele. Analysis was performed in men and women separately with
no adjustment for any covariates. A further analysis was carried
out conditional on the enhancer region SNP rs247616, which itself
was strongly associated with HDL levels. The Whitehall II
analyses were not adjusted for use of lipid-lowering drugs because
the prevalence was generally low; of 5059 total individuals from
WH-II, 39 (0.8%) were taking lipid-lowering medication at the
time of lipid measurement [25].
INVEST-GENES
Baseline characteristics were compared using chi-squared test or
analysis of variance. To minimize population stratification in the
diverse population of INVEST, all analyses were conducted
separately by race/ethnicity. For the INVEST-GENES case-
control samples, adjusted odds ratios (ORs) and 95% confidence
intervals (CIs) for occurrence of the primary outcome were
calculated using logistic regression. Assuming alpha level of 0.05,
at minor allele frequency of 6%, we have .90% power to detect a
SNP main effect with OR of 2 or greater. However, in order to
have .80% power to detect SNP*treatment interaction OR of 2
or greater, 4 times as many patients would be needed.
Supporting Information
Figure S1 CETP Gene structure, including locations of
the main CETP polymorphisms determined in this
study.
(TIFF)
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Figure S2 Mfold RNA folding predictions of CETP exon
9. The rs5883 T variant influences internal base pairing of the
exon. This causes changes in nucleotide access at both 59 and 39
ends of the exon.
(TIFF)
Figure S3 Allelic expression and splice assay standard
curves. Plasmid DNA containing either the A or G allele of
I405V, or the normal (long splice) or D9 (short splice) isoform of
CETP was diluted over 3 orders of magnitude. Allele specific or
splice specific primers were used to amplify and quantitate the
samples via Real-Time PCR in SYBR Green Master Mix (Applied
Biosystems). Each point represents the average of 3 standard
curves.
(TIFF)
Figure S4 Correlation between Real-Time and fluores-
cent assay results. Correlation between allele specific Real
Time PCR (RT) assays and SNaPshot Primer Extension (PE)
assays (panel A), or splice specific Real-Time PCR (RT) assays and
fluorescent splice specific primer assays (panel B) performed on the
ABI 3730. Nine samples were analyzed in duplicate.
(TIFF)
Figure S5 Linkage Structure of Genotyped CETP SNPs
in Liver. Thirteen SNP’s were genotyped in 94 livers. Pairwise
LD correlation R2 is shown on the horizontal axis. Pairwise D9 is
shown on the vertical axis. Calculated and graphed using Helix
Tree Genetic Analysis Software Package.
(TIF)
Table S1 PCR primers and amplicons for rs993076 and
the CETP splice variant (other primers are available on
request). rs5883 was determined using preselected commercial
TaqMan and PCR probes (Life Technologies, Foster City, CA).
(DOCX)
Table S2 Table of polymorphisms in the CETP locus
genotyped in the liver study, and genotyping methods.
Not all of the SNPs were analyzed in each liver, so that the allele
frequencies reflect some selection bias and may not represent allele
frequencies in the clinical groups in this study.
(DOCX)
Table S3 Estimated CETP haplotypes constructed from
5 SNPs genotyped in 44 liver samples (calculated with
HelixTree). rs5883 and rs9930761 are in complete LD in the
liver samples tested for all SNPs in these tissues. The EM
probability represents ambiguity in calling the individual haplo-
types.
(DOCX)
Table S4 A. Association p values between CETP SNPs and log-
transformed HDL-C levels in the Whitehall II study (4,744
subjects, males plus females). SNPs with available rs id number
and unadjusted p value ,0.001 were included. B. Mean HDL-C
levels grouped by genotype for rs247616 and rs5883 in all subjects.
C. Significant interaction between effects of rs5883 and rs247616
on HDL-C levels.
(DOCX)
Table S5 A. Allele associations between CETP polymorphisms
and primary outcomes in the INVEST-GENES study (464 males
and 402 females, all Caucasians) using an additive model. The
SNPs in this table are sorted by chromosomal location. The p
values are unadjusted. B. Minor allele frequencies and LD
between rs9930761 and rs5883 in the INVEST cohort.
(DOCX)
Table S6 Published allele frequencies of rs9930761 in
various populations (http://www.ncbi.nlm.nih.gov/projects/
SNP/snp_ref.cgi?rs = 9930761) (September 2010).
(DOCX)
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